Pharma marketing ke naye rules banane wali committee par sawal uth gaye hain. 'Working Group on Access to Medicines' ne conflict of interest ka mudda uthaya hai, jisse UCPMP 2024 implementation mein deri ho sakti hai.
Department of Pharmaceuticals ki 3-member wali expert committee mushkil mein hai. 'Working Group on Access to Medicines and Treatments' ne maang ki hai ki committee ko fir se banaya jaye. Inka kehna hai ki Dr. Naresh Trehan ka Medanta hospital group se judna 'Conflict of Interest' create karta hai.
Committee ka maqsad kya hai?
UCPMP 2024 ka main goal ye hai ki Pharma companies aur Doctors/Hospitals ke beech ke unethical marketing practices ko roka jaye aur dawaon par hone wale extra markups ko control kiya jaye.
Investors ke liye ye kyun zaroori hai?
Pharma sector mein marketing aur doctor-client interaction ek bahut bada cost center hota hai. Agar government ne strict rules lagu kiye, toh companies ko apni strategy badalni padegi, jiska seedha asar unke Margins aur Operational Expenses par pad sakta hai.
Iske alawa, NPPA (National Pharmaceutical Pricing Authority) ne pehle bhi Delhi-NCR, UP, Maharashtra aur Karnataka mein overcharging ke cases pakde the, jahan hospital pricing mein Pharma products ke markups ka bada role tha. Ab ministry kya reaction deti hai aur committee structure mein kya badlav aate hain, ye dekhna hoga. Tab tak Pharma stocks par nazar rakhein, kyunki koi bhi policy delay market sentiment ko affect kar sakta hai.